Floradapt Intensive GI
Phase 2Small molecule
Floradapt Intensive GI is one of 21 small molecule programs targeting Chronic Fatigue Syndrome. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Chronic Fatigue Syndrome
#DrugCompanyPhaseTrials
1Xyrem
Jazz PharmaceuticalsApproved
Sunosi
AAxsome Therapeutics, Inc.
Approved
Rituxan
RochePhase 3
Lisdexamfetamine Dimesylate
TakedaApproved
Northera
LundbeckPhase 2
Cymbalta
Alnylam PharmaceuticalsPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Enbrel
IImmunex
Phase 2
Kineret
SSwedish Orphan Biovitrum
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Floradapt Intensive GI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNova Southeastern University